CurrentBlue KCPolicy POL-PP-303

Prescription Medication and Illicit Drug Testing in the Outpatient Setting

Defines coverage and billing rules for presumptive and definitive outpatient drug testing, including reimbursement criteria, exclusions (e.g., specimen validity testing and certain proprietary assays), coding guidance, and frequency limits; applies to professional/facility providers and laboratories submitting outpatient drug testing claims.

Policy Summary

PayerBlue KC

PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting

Policy CodePolicy POL-PP-303

Change TypeNo material changes

Effective DateJul 1, 2025

Next Review DateJul 1, 202618d

Key ActionOrder presumptive urine drug screening only when clinically indicated and document rationale; request definitive testing with physician-documented rationale when presumptive results are discordant or specific identification/concentration is needed.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

G0480–G0483, 80305–80307listed codes

up to 7definitive classes reimbursed

1-4/yrpresumptive monitoring events

not reimbursedspecimen validity testing

excluded

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria and exclusions

Coverage criteria and exclusions for outpatient drug testing

Coverage is conditional based on clinical indication, documented rationale, and member benefit; certain tests and situations are excluded from coverage.

ALL of the following

ONE of
- Assessment prior to initiating chronic opioid therapy to determine exposure to controlled substances or illicit drugs (documented history/signs/symptoms).
- Routine monitoring during chronic opioid therapy with frequency based on documented risk stratification: low risk up to 1 time per year; moderate risk up to 2 times per year; high risk up to 4 times per year.
- Testing at time of visit for individuals with aberrant behavior (e.g., lost prescriptions, multiple early refill requests, opioids from multiple providers, unauthorized dose escalation, apparent intoxication).
- High-risk pregnant individuals when suspicion for substance use exists (based on screening questions or PDMP information), documented in the medical record.
- Newborns when there is a history of maternal substance abuse or when the birthing parent has agitated/altered mental status.
- Organ transplant candidates with a history of substance abuse to demonstrate abstinence prior to transplant.
- Individuals with suspected or diagnosed mental illness (e.g., anxiety disorders, schizophrenia, major depressive disorder, mood disorders, suicidal ideation, substance use disorder).
- Individuals with attention-deficit hyperactivity disorder or disruptive behavior disorders.
- Cancer patients receiving opioid pain medication.
- Individuals with epilepsy.
- Management and compliance monitoring of an individual under treatment for substance abuse or dependence with documented monitoring frequency: 0–90 days abstinence: 1–2 random qualitative tests per week; >90 days abstinence: 1–3 random qualitative tests per month; and testing when substance abuse is in the differential diagnosis of the presenting condition.

ALL of the following

Definitive/confirmatory testing requested for panels larger than seven drug classes may not be reimbursed.
Confirmatory or presumptive drug testing using certain proprietary tests (for example, CareView360) may not be reimbursed.
Specimen validity testing (e.g., urine specific gravity, creatinine, pH, urine oxidant level, genetic identity testing such as NextGen Precision™) may not be reimbursed.
This policy does not apply to state- or federally-mandated forensic/court-ordered testing, pre-employment or job-related testing, routine physical exams, urgent/emergency care, or routine behavioral health assessments (these settings are excluded from coverage under this policy).

Included CPT/HCPCS and proprietary laboratory codes

Included CPT/HCPCS CodesCPT

80305	Presumptive drug test(s) read by direct optical observation; includes sample validation when performed
80306	Presumptive drug test(s) read by instrument-assisted direct optical observation; includes sample validation when performed
80307	Presumptive drug test(s) by instrument chemistry analyzers or chromatography/mass spectrometry; includes sample validation when performed
G0480	Definitive drug test(s), 1-7 drug classes; includes specimen validity testing
G0481	Definitive drug test(s), 8-14 drug classes; includes specimen validity testing
G0482	Definitive drug test(s), 15-21 drug classes; includes specimen validity testing
G0483	Definitive drug test(s), continued range per code description
G0659	Qualitative or quantitative, includes specimen validity testing; 22 or more drug classes

Included Proprietary Laboratory (U-) Codesmixed

0007U	Presumptive with definitive confirmation including specimen verification (proprietary test: ToxProtect)
0011U	Prescription drug monitoring, oral fluid LC-MS/MS (proprietary: Cordant CORE™)
0051U	Prescription drug monitoring, urine 31 drug panel quantitative (proprietary: UCompliDx)
0054U	Prescription drug monitoring, 14+ classes definitive tandem mass spectrometry, capillary blood (proprietary: AssuranceRx Micro Serum)
0079U	Comparative DNA analysis for specimen identity verification (ToxLok™)
0082U	Definitive 90+ drugs and presumptive any number, proprietary NextGen Precision™
0093U	Prescription drug monitoring, 65 common drugs by LC-MS/MS (ComplyRX)
0227U	Presumptive drug assay, 30+ drugs, LC-MS/MS
0328U	Definitive 120+ drugs and metabolites, quantitative LC-MS/MS (proprietary: CareView360)

Definitive panel class limit reimbursed

Reimbursed definitive panel sizeUp to 7 drug classes generally reimbursed for definitive (confirmatory) testing

Larger panelsDefinitive testing requested for panels larger than seven drug classes may not be reimbursed

Documentation requirementLaboratory-based definitive testing must be requested with documented rationale by the treating physician when clinically indicated

Definitive proprietary tests

Proprietary test reimbursementCertain proprietary tests (example: CareView360) may not be reimbursed for presumptive or definitive drug testing

ExamplesProprietary assays listed in coding (e.g., CareView360/0328U and other vendor 'U' codes) are subject to exclusion under this policy

Reimbursement conditions and provider requirements

Documentation Required

Reimbursement conditions for presumptive and definitive outpatient drug testing

Reimbursement for outpatient presumptive and definitive drug testing is conditional on documented clinical indication, appropriate test selection, and adherence to frequency limits. Providers must document the medical necessity in the patient's medical record (history, clinical findings, risk assessment, treatment plan, and rationale for test type and frequency). Laboratory-based definitive testing must be specifically requested by the treating clinician with rationale documented. Proprietary point-of-care confirmatory assays are not reimbursed.

Document: clinical indication, risk assessment, treatment/monitoring plan, test type requested, and justification in the medical record.
Presumptive testing allowed for chronic non-cancer pain assessment, initiation and monitoring of opioid therapy, and other listed clinical scenarios per policy.
Definitive testing requires clinician request and documented rationale; allowed when presumptive results conflict with clinical picture or when specificity/quantitation is required.
Adhere to frequency limits tied to risk level and duration of abstinence; exceeding these limits may be denied.
Do not bill for proprietary tests (e.g., CareView360) or definitive panels >7 drug classes — these are not reimbursed.

Key definitions

Drug testing / TDM / Forensic testing

Definition — Drug testing (clinical)Laboratory analyses of biological specimens to detect drugs of abuse; urine is the most commonly tested biological substance

Forensic testingTesting performed for legal proceedings; requires secondary confirmatory testing and is not addressed by this outpatient clinical policy

Therapeutic drug monitoring (TDM)Sampling of plasma or serum drug levels to determine optimal drug dosing; TDM is outside the scope of this policy

Specimen validity testing

Specimen validity testing — definitionAnalyses such as urine specific gravity, urine creatinine, pH, urine oxidant level, or genetic identity testing used to assess sample integrity

Reimbursement statusSpecimen validity testing may not be reimbursed under this policy